Innovations in Synthetic Biology and Sequencing Technology

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences trends across synthetic biology and sequencing technology. Engineered chimeric molecules and promoters, nanobody platforms, next-generation RNA sequencing technologies coupled with machine learning systems, are some of the most relevant innovations profiled. Vector delivery platform technologies expected to undergo clinical studies in the coming quarter are also depicted.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut o

Table of Contents

Innovations in Synthetic Biology and Sequencing TechnologyRecent Advances in Synthetic Biology and Sequencing TechnologyEngineered Chimeric Molecule Targeting HER GenesNext-gen RNA Sequencing Coupled with Machine LearningEngineered Promoters May Hold Key to Controlling Gene ExpressionNanobody Technology Facilitated ImmunotherapyClinical Trial Analysis and Key ContactsClinical Trial Analysis of Vector-delivery Based DrugsKey Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.